FI963170A0 - Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i - Google Patents
Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks iInfo
- Publication number
- FI963170A0 FI963170A0 FI963170A FI963170A FI963170A0 FI 963170 A0 FI963170 A0 FI 963170A0 FI 963170 A FI963170 A FI 963170A FI 963170 A FI963170 A FI 963170A FI 963170 A0 FI963170 A0 FI 963170A0
- Authority
- FI
- Finland
- Prior art keywords
- identifying individuals
- cellular abnormalities
- abnormalities
- cellular
- individuals
- Prior art date
Links
- 230000005856 abnormality Effects 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/195,186 US5558995A (en) | 1993-01-22 | 1994-02-14 | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
US08/196,630 US5683886A (en) | 1993-06-17 | 1994-02-15 | Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof |
US08/292,492 US6328971B1 (en) | 1993-01-22 | 1994-08-18 | MAGE-1 derived nona peptides, and compositions thereof |
PCT/US1995/001446 WO1995021630A1 (en) | 1994-02-14 | 1995-01-26 | Methods for identifying individuals suffering from a cellular abnormality |
Publications (2)
Publication Number | Publication Date |
---|---|
FI963170A FI963170A (fi) | 1996-08-13 |
FI963170A0 true FI963170A0 (fi) | 1996-08-13 |
Family
ID=27393408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI963170A FI963170A0 (fi) | 1994-02-14 | 1996-08-13 | Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i |
Country Status (14)
Country | Link |
---|---|
US (1) | US6328971B1 (fi) |
EP (1) | EP0789591B1 (fi) |
JP (1) | JP2002502224A (fi) |
AT (1) | ATE237685T1 (fi) |
AU (1) | AU697246B2 (fi) |
CA (1) | CA2182969A1 (fi) |
DE (1) | DE69530410T2 (fi) |
DK (1) | DK0789591T3 (fi) |
ES (1) | ES2197196T3 (fi) |
FI (1) | FI963170A0 (fi) |
NO (1) | NO963347L (fi) |
NZ (1) | NZ282938A (fi) |
PT (1) | PT789591E (fi) |
WO (1) | WO1995021630A1 (fi) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US5877017A (en) * | 1993-06-17 | 1999-03-02 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
WO2002044723A2 (en) * | 2000-11-28 | 2002-06-06 | Eileen Louise Rice Mcfarland | Method for diagnosing a predisposition of psychosis in a progeny |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066783A (en) * | 1986-05-20 | 1991-11-19 | Cohen Eric A | Antiviral peptides and means for treating herpes infections |
DE69233774D1 (de) * | 1991-01-21 | 2009-12-10 | Elan Pharm Inc | Prüfung und Modell für Alzheimers-Krankheit |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
US5558995A (en) * | 1993-01-22 | 1996-09-24 | Ludwig Institute For Cancer Research | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
CA2154468A1 (en) * | 1993-01-22 | 1994-08-04 | Pierre Van Der Bruggen | Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1 |
ATE466869T1 (de) * | 1993-03-05 | 2010-05-15 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
JPH10511639A (ja) * | 1994-09-30 | 1998-11-10 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | 腫瘍拒絶抗原前駆体または腫瘍拒絶抗原を含有する組成物ならびにアジュバント及び/又は成長因子 |
-
1994
- 1994-08-18 US US08/292,492 patent/US6328971B1/en not_active Expired - Lifetime
-
1995
- 1995-01-26 EP EP95913476A patent/EP0789591B1/en not_active Expired - Lifetime
- 1995-01-26 DE DE69530410T patent/DE69530410T2/de not_active Expired - Lifetime
- 1995-01-26 DK DK95913476T patent/DK0789591T3/da active
- 1995-01-26 PT PT95913476T patent/PT789591E/pt unknown
- 1995-01-26 CA CA002182969A patent/CA2182969A1/en not_active Abandoned
- 1995-01-26 AU AU20899/95A patent/AU697246B2/en not_active Ceased
- 1995-01-26 NZ NZ282938A patent/NZ282938A/xx unknown
- 1995-01-26 ES ES95913476T patent/ES2197196T3/es not_active Expired - Lifetime
- 1995-01-26 JP JP52127195A patent/JP2002502224A/ja not_active Ceased
- 1995-01-26 WO PCT/US1995/001446 patent/WO1995021630A1/en active IP Right Grant
- 1995-01-26 AT AT95913476T patent/ATE237685T1/de active
-
1996
- 1996-08-12 NO NO963347A patent/NO963347L/no not_active Application Discontinuation
- 1996-08-13 FI FI963170A patent/FI963170A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
WO1995021630A1 (en) | 1995-08-17 |
DE69530410D1 (de) | 2003-05-22 |
US6328971B1 (en) | 2001-12-11 |
NZ282938A (en) | 2000-01-28 |
FI963170A (fi) | 1996-08-13 |
EP0789591A4 (en) | 1998-07-01 |
NO963347D0 (no) | 1996-08-12 |
ES2197196T3 (es) | 2004-01-01 |
EP0789591B1 (en) | 2003-04-16 |
ATE237685T1 (de) | 2003-05-15 |
AU2089995A (en) | 1995-08-29 |
PT789591E (pt) | 2003-08-29 |
AU697246B2 (en) | 1998-10-01 |
DE69530410T2 (de) | 2004-03-25 |
EP0789591A1 (en) | 1997-08-20 |
JP2002502224A (ja) | 2002-01-22 |
DK0789591T3 (da) | 2003-05-19 |
CA2182969A1 (en) | 1995-08-17 |
NO963347L (no) | 1996-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
DE69522965D1 (de) | Verbindungen und methoden für die stimulierungen und die erhöhung von schutzimmunantworten und il-12 herstellung | |
ES2138729T3 (es) | Metodos de diagnostico de la preeclampsia. | |
ATE308045T1 (de) | Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür | |
NO952385L (no) | Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen | |
ATE374618T1 (de) | Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen | |
FI963170A0 (fi) | Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i | |
CA2184175A1 (en) | Isolated, tyrosinase derived peptides and uses thereof | |
DE69626816D1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
HUP0001167A2 (hu) | Fertőzés és gyulladás képi megjelenítésére szolgáló radiokészítmények | |
DK1039931T3 (da) | Multivalente rekombinante antistoffer til at behandle HRV infektioner | |
ATE62789T1 (de) | Mittel zur bekaempfung von phytopathogenen mikroben. | |
NZ514691A (en) | Method to type prion proteins | |
UA33330A (uk) | Спосіб діагностики ендогенної інтоксикації | |
ITCZ980005A0 (it) | Apparecchiatura per la diagnosi precoce di patologie umane e relativa metodica. | |
Wilde | APPLICATION OF THE ARTICULATION INDEX TO HEARING CONSERVATION. | |
UA28113C2 (uk) | Спосіб експрес-тестування ефективності реабілітації здоров'я людини | |
MX9606031A (es) | Inhibidores de cetona perfluoroalquilica de elastasa y procesos para fabricarlos. | |
UA25368A (uk) | Спосіб лікуваhhя виразкової хвороби шлуhка та дваhадцятипалої кишки, що асоційоваhа helicobakter pilori | |
UA34214A (uk) | Спосіб діагностики персистируючої хламідійної інфекції |